Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

S-1360 Shionogi-GlaxoSmithKline.

Andreas Billich1

  • 1Novartis Research Institute, PO Box 80, Brunner Strasse 59, 1235 Vienna, Austria. billich@pharma.novartis.com

Current Opinion in Investigational Drugs (London, England : 2000)
|April 3, 2003
PubMed
Summary

Shionogi-GlaxoSmithKline Pharmaceuticals is developing S-1360, an investigational HIV integrase inhibitor. Ongoing Phase II trials in October 2002 suggest a potential 2004/2005 launch for this novel HIV infection treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structure-Based and Property-Driven Optimization of <i>N</i>-Aryl Imidazoles toward Potent and Selective Oral RORγt Inhibitors.

Journal of medicinal chemistry·2019
Same author

Optimizing a Weakly Binding Fragment into a Potent RORγt Inverse Agonist with Efficacy in an in Vivo Inflammation Model.

Journal of medicinal chemistry·2018
Same author

Interferon regulatory factor 5 and nuclear factor kappa-B exhibit cooperating but also divergent roles in the regulation of pro-inflammatory cytokines important for the development of TH1 and TH17 responses.

The FEBS journal·2018
Same author

Pharmacological inhibition of RORγt suppresses the Th17 pathway and alleviates arthritis in vivo.

PloS one·2017
Same author

Feasibility and physiological relevance of designing highly potent aminopeptidase-sparing leukotriene A4 hydrolase inhibitors.

Scientific reports·2017
Same author

Retinoic-acid-orphan-receptor-C inhibition suppresses Th17 cells and induces thymic aberrations.

JCI insight·2017

Area of Science:

  • Infectious Diseases
  • Virology
  • Pharmacology

Background:

  • Human Immunodeficiency Virus (HIV) infection remains a significant global health challenge.
  • Antiretroviral therapies are crucial for managing HIV, with ongoing research for improved treatments.
  • Integrase inhibitors represent a key class of antiretroviral drugs.

Purpose of the Study:

  • To evaluate the development of S-1360, a novel HIV integrase inhibitor.
  • To assess the progress of S-1360 through clinical trials for HIV treatment.

Main Methods:

  • Development of S-1360 by Shionogi and GlaxoSmithKline.
  • Conducting Phase II clinical trials to assess safety and efficacy.
  • Monitoring trial progress as of October 2002.

Main Results:

  • Phase II trials for S-1360 were actively ongoing as of October 2002.
  • S-1360 is being developed as a potential treatment for HIV infection.

Conclusions:

  • S-1360 shows promise as a future therapeutic option for individuals with HIV.
  • Anticipated market launch for S-1360 is projected for 2004/2005, pending successful trial completion.

Related Experiment Videos